Business News • PR NewsWire • Cempra Pharmaceuticals Presents New Data on Its Multi-Drug Resistant Anti-Infective Portfolio, CEM-101 and TAKSTA(TM) (CEM-102), at the 20th European Congress of Clinical Microbiology and Infectious Disease

Cempra Pharmaceuticals Presents New Data on Its Multi-Drug Resistant Anti-Infective Portfolio, CEM-101 and TAKSTA(TM) (CEM-102), at the 20th European Congress of Clinical Microbiology and Infectious Disease

Cempra Pharmaceuticals Presents New Data on Its Multi-Drug Resistant Anti-Infective Portfolio, CEM-101 and TAKSTA(TM) (CEM-102), at the 20th European Congress of Clinical Microbiology and Infectious Disease

CHAPEL HILL, N.C., Apr. 10 /PRNewswire/ -- Cempra Pharmaceuticals today announced poster presentations on its novel antibiotic CEM-101, a next-generation macrolide, and CEM-102 (TAKSTA), the company's proprietary front-loading oral dosing regimen of sodium fusidate, at the 20th European Congress of

View More : http://www.prnewswire.com/news-releases/cempra-pharmaceuticals-presents-new-data-on-its-multi-drug-resistant-anti-infect...

Releted News by prnewswire

Positive Results from Optimer Pharmaceuticals' Second Phase 3 Study of Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI) Presented at ECCMID

Teamsters Protest Honda at NY Auto Show

'VH1's Tough Love Couples' Get Frisky at Del Frisco's